Abiraterone and Increased Survival in Metastatic Prostate Cancer

Autor: de Bono, Johann S., Logothetis, Christopher J., Molina, Arturo, Fizazi, Karim, North, Scott, Chu, Luis, Chi, Kim N., Jones, Robert J., Goodman, Oscar B., Saad, Fred, Staffurth, John N., Mainwaring, Paul, Harland, Stephen, Flaig, Thomas W., Hutson, Thomas E., Cheng, Tina, Patterson, Helen, Hainsworth, John D., Ryan, Charles J., Sternberg, Cora N., Ellard, Susan L., Fléchon, Aude, Saleh, Mansoor, Scholz, Mark, Efstathiou, Eleni, Zivi, Andrea, Bianchini, Diletta, Loriot, Yohann, Chieffo, Nicole, Kheoh, Thian, Haqq, Christopher M., Scher, Howard I., COU-AA-301 Investigators, [missing], Rottey, Sylvie
Rok vydání: 2011
Předmět:
Male
CASTRATION
PLUS PREDNISONE
Kaplan-Meier Estimate
Antiandrogen
Androgen deprivation therapy
Prostate cancer
chemistry.chemical_compound
TESTOSTERONE
Antineoplastic Combined Chemotherapy Protocols
Medicine and Health Sciences
Neoplasm Metastasis
CYP17A1 Inhibitor
Fatigue
DOCETAXEL
Androstenols
Apalutamide
Abiraterone acetate
I CLINICAL-TRIAL
Steroid 17-alpha-Hydroxylase
General Medicine
Middle Aged
Treatment Outcome
Androgens
Disease Progression
Hormonal therapy
Androstenes
medicine.medical_specialty
medicine.drug_class
Urology
HUMAN CYTOCHROME P450(17-ALPHA)
Article
CYP17
Double-Blind Method
ACETATE
medicine
Humans
Orteronel
Aged
business.industry
Prostatic Neoplasms
Androgen Antagonists
medicine.disease
Survival Analysis
Surgery
chemistry
Prednisone
ANDROGEN-DEPRIVATION THERAPY
business
HORMONAL-THERAPY
Zdroj: NEW ENGLAND JOURNAL OF MEDICINE
ISSN: 1533-4406
0028-4793
DOI: 10.1056/nejmoa1014618
Popis: BACKGROUND Biosynthesis of extragonadal androgen may contribute to the progression of castration-resistant prostate cancer. We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy. METHODS We randomly assigned, in a 2: 1 ratio, 1195 patients who had previously received docetaxel to receive 5 mg of prednisone twice daily with either 1000 mg of abiraterone acetate (797 patients) or placebo (398 patients). The primary end point was overall survival. The secondary end points included time to prostate-specific antigen (PSA) progression (elevation in the PSA level according to prespecified criteria), progression-free survival according to radiologic findings based on prespecified criteria, and the PSA response rate. RESULTS After a median follow-up of 12.8 months, overall survival was longer in the abiraterone acetate-prednisone group than in the placebo-prednisone group (14.8 months vs. 10.9 months; hazard ratio, 0.65; 95% confidence interval, 0.54 to 0.77; P
Databáze: OpenAIRE
Externí odkaz: